Dose a novel biomarker, RM2-Haptoglobin-beta, has the possibility to exceed PSA in predicting outcome of prostate cancer?

点击翻译按钮获取中文摘要

In our previous study, haptoglobin-beta chain defined by RM2 is a novel serum marker that may be useful for detection of early prostate cancer when coupled with PSA as or gan-specific marker because it is not specific to prostate cancer. In current study, we tried to establish the assay system of detecting haptoglobin-beta chain defined by RM2 from sera of prostate cancer patients.There were no correlation between concentrations of haptoglobin and PSA. And more, there were no differences in concentrations of haptoglobin between sera of prostate cancer and sera of benign prostate disease. So it is necessary to improve the quality of detecting system of haptoglobin-beta chain defined by RM2.